Comparison of age-related macular degeneration treatments trials: Lucentis-avastin trial (CATT).

Trial Profile

Comparison of age-related macular degeneration treatments trials: Lucentis-avastin trial (CATT).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms CATT
  • Most Recent Events

    • 07 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 29 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Feb 2017.
    • 02 May 2016 Long-term results of this trial were published in Ophthalmology, according to an American Academy of Ophthalmology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top